JP2013522350A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522350A5 JP2013522350A5 JP2013500572A JP2013500572A JP2013522350A5 JP 2013522350 A5 JP2013522350 A5 JP 2013522350A5 JP 2013500572 A JP2013500572 A JP 2013500572A JP 2013500572 A JP2013500572 A JP 2013500572A JP 2013522350 A5 JP2013522350 A5 JP 2013522350A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition
- vegf
- use according
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 33
- 206010033078 Otitis media Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 108091008605 VEGF receptors Proteins 0.000 claims description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 6
- KUFRQPKVAWMTJO-LMZWQJSESA-N alvespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-LMZWQJSESA-N 0.000 claims description 6
- 230000037361 pathway Effects 0.000 claims description 6
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 3
- 101710113864 Heat shock protein 90 Proteins 0.000 claims description 3
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 229960003787 sorafenib Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 10
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 2
- 229950000578 vatalanib Drugs 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1004761.1A GB201004761D0 (en) | 2010-03-22 | 2010-03-22 | Method |
| GB1004761.1 | 2010-03-22 | ||
| PCT/GB2011/000382 WO2011117568A1 (en) | 2010-03-22 | 2011-03-18 | Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013522350A JP2013522350A (ja) | 2013-06-13 |
| JP2013522350A5 true JP2013522350A5 (OSRAM) | 2014-03-06 |
Family
ID=42228117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013500572A Pending JP2013522350A (ja) | 2010-03-22 | 2011-03-18 | 中耳炎の処置において使用するためのソラフェニブもしくはバタラニブなどのｖｅｇｆおよび／またはｈｉｆ経路を標的とする化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20130078260A1 (OSRAM) |
| EP (1) | EP2549989A1 (OSRAM) |
| JP (1) | JP2013522350A (OSRAM) |
| CN (1) | CN102905697A (OSRAM) |
| AU (1) | AU2011231405A1 (OSRAM) |
| CA (1) | CA2793643A1 (OSRAM) |
| GB (1) | GB201004761D0 (OSRAM) |
| WO (1) | WO2011117568A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016073647A2 (en) * | 2014-11-04 | 2016-05-12 | University Of Southern California | COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS |
| MY207644A (en) * | 2017-12-19 | 2025-03-07 | Akouos Inc | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| WO2022119839A1 (en) | 2020-12-01 | 2022-06-09 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| CN112807293B (zh) * | 2021-03-01 | 2023-06-02 | 青岛大学 | 甲磺酸去铁胺在制备治疗中耳炎药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7718624B2 (en) * | 2004-09-01 | 2010-05-18 | Sitkovsky Michail V | Modulation of immune response and inflammation by targeting hypoxia inducible factors |
| EP1838303B1 (en) * | 2004-12-30 | 2011-02-09 | Bioresponse LLC | Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions |
| WO2008094208A2 (en) * | 2006-08-02 | 2008-08-07 | Northwestern University | Protein kinase targeted therapeutics |
-
2010
- 2010-03-22 GB GBGB1004761.1A patent/GB201004761D0/en not_active Ceased
-
2011
- 2011-03-18 CA CA2793643A patent/CA2793643A1/en not_active Abandoned
- 2011-03-18 US US13/636,097 patent/US20130078260A1/en not_active Abandoned
- 2011-03-18 JP JP2013500572A patent/JP2013522350A/ja active Pending
- 2011-03-18 WO PCT/GB2011/000382 patent/WO2011117568A1/en not_active Ceased
- 2011-03-18 EP EP11710237A patent/EP2549989A1/en not_active Withdrawn
- 2011-03-18 CN CN2011800254426A patent/CN102905697A/zh active Pending
- 2011-03-18 AU AU2011231405A patent/AU2011231405A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2013000309A1 (en) | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents | |
| JP2018522858A5 (OSRAM) | ||
| HRP20151399T1 (hr) | Kinazni inhibitor koji regulira signalni put apoptoze | |
| JP2017537070A5 (OSRAM) | ||
| JP2012136541A5 (OSRAM) | ||
| EP4548972A3 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
| EA201390428A1 (ru) | Композиции и способы лечения легочной гипертензии | |
| UA108369C2 (uk) | Піролопіримідини як інгібітори cdk4/6 | |
| SG10201805033XA (en) | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| EA201590457A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| WO2011022440A3 (en) | Heat shock protein binding compounds, compositions, and methods for making and using same | |
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| EA201790765A1 (ru) | Производные спиродиамина в качестве ингибиторов альдостерон-синтазы | |
| BR112013032711A2 (pt) | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase | |
| MX2013011691A (es) | Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| CN108026053A8 (zh) | 作为mIDH1抑制剂的稠合的咪唑类化合物 | |
| UA112549C2 (uk) | Частинки на основі поліакрилату, що містять активну сполуку | |
| WO2013061004A8 (fr) | Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines | |
| WO2013142182A3 (en) | Combination therapy of a mek inhibitor and igf1r inhibitor | |
| ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
| WO2013040227A3 (en) | Therapeutic compounds | |
| IN2015DN00528A (OSRAM) | ||
| MX2015000746A (es) | Terapia de combinacion de inhibidores para el receptor del factor de crecimiento insulinico tipo 1 (igf1r) y fosfatidilinositol 3-cinasa (pi3k). |